StratifAI Partners with Memorial Sloan Kettering to Validate AI-Powered Breast Cancer Biomarker Platform
核心洞察
StratifAI (搜索) has been selected for Memorial Sloan Kettering (搜索)'s iHub Challenge 2025 Cohort program, providing access to extensive clinical datasets to validate its Polaris™ (搜索) AI platform.
The Polaris™ (搜索) platform transforms routine clinical data into novel biomarkers for precision oncology, eliminating the need for costly specialized inputs and enabling global scalability.
The collaboration focuses on validating Polaris™ Breast (搜索), a diagnostic test that assesses recurrence risk in early-stage breast cancer (搜索) using digitized histology slides.
StratifAI (搜索), an AI precision oncology company, has been selected for Memorial Sloan Kettering (搜索)'s (MSK (搜索)) iHub Challenge 2025 Cohort program, marking a significant step toward validating its artificial intelligence-powered biomarker platform. The collaboration will provide StratifAI with access to MSK's extensive clinical datasets and direct collaboration opportunities with leading clinicians and researchers to accelerate validation of its Polaris™ (搜索) platform.
Transforming Biomarker Discovery Through AI
For decades, biomarker discovery has been constrained by high costs, slow processes, and narrow scope. StratifAI (搜索)'s Polaris™ (搜索) platform addresses these limitations through a fully digital, multimodal AI approach that transforms routine clinical data—already integral to everyday care—into novel biomarkers that guide treatment decisions. By eliminating the need for costly and specialized inputs, Polaris™ is designed for global scalability and broad access to precision oncology.
Through MSK (搜索)'s resources, StratifAI (搜索) will further validate Polaris™ (搜索) on real-world clinical data as it advances toward regulatory approval and guideline inclusion in the EU and US. The collaboration aims not only to accelerate validation during the Challenge but also hopes to establish a foundation for extended collaboration, building pathways that support ongoing validation of Polaris™ in diverse clinical contexts.
Strategic Partnership with Clinical Impact
"Validating Polaris™ (搜索) on thousands of patient samples from MSK (搜索) is a decisive stride toward clinical certification and guideline inclusion across major healthcare systems," said Omar El Nahhas, CEO and co-founder of StratifAI (搜索). "Partnering with MSK's world-class clinicians and researchers allows us to refine the platform and advance our mission of enabling global access to top-tier cancer (搜索) care."
Rick Peng, who manages the iHub program and serves as Lead, Digital Ventures, in MSK (搜索)'s Office of Entrepreneurship & Commercialization, expressed enthusiasm for the partnership: "We are excited to work with StratifAI (搜索) as part of the MSK iHub Challenge 2025 Cohort. Throughout our competitive evaluation and selection process for this Cohort, it was clear that StratifAI has a focus on technology innovations that can be accelerated to impact through support from MSK."
Focus on Breast Cancer Recurrence Assessment
This collaboration builds on StratifAI (搜索)'s ongoing validation of Polaris™ Breast (搜索), a test designed to assess recurrence risk in early-stage breast cancer (搜索). The diagnostic assesses metastatic risk in early breast cancer (搜索) directly from digitized histology slides, supporting better treatment decisions. By combining exclusive data access partnerships across Europe and the United States, StratifAI is generating the robust clinical evidence required for regulatory approval, reimbursement, and integration into international treatment guidelines.
Polaris™ Breast (搜索) has been retrospectively validated on thousands of patients from Phase III trials and real-world clinical settings. The diagnostic is currently available for research use only and is undergoing regulatory approval in the EU and US.
Platform Technology and Applications
StratifAI (搜索)'s discovery platform applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers (搜索). The platform's approach to transforming routine clinical data into actionable biomarkers represents a potential paradigm shift in precision oncology, offering the possibility of making advanced cancer (搜索) diagnostics more accessible globally.